Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.75 |
| ▸ | NOD1 | Q9Y239 | 14/20 | 0.65 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28183786 | 1.00 | SLC6A5 (0.75) | SLC6A5NOD1FOLH1ITGB3ITGA2B | |
| SCHEMBL1043507 | 0.95 | SLC6A5 (0.82) | SLC6A5NOD1FOLH1ITGB3ITGA2B | |
| SCHEMBL341123 | 0.95 | SLC6A5 (0.82) | SLC6A5NOD1FOLH1ITGB3ITGA2B | |
| SCHEMBL9716739 | 0.94 | SLC6A5 (0.85) | SLC6A5NOD1FOLH1ITGB3ITGA2B | |
| SCHEMBL5946236 | 0.94 | SLC6A5 (0.85) | SLC6A5NOD1FOLH1ITGB3ITGA2B | |
| SCHEMBL342965 | 0.94 | SLC6A5 (0.85) | SLC6A5NOD1FOLH1ITGB3ITGA2B | |
| SCHEMBL343693 | 0.94 | SLC6A5 (0.85) | SLC6A5NOD1FOLH1ITGB3ITGA2B | |
| SCHEMBL9716727 | 0.94 | SLC6A5 (0.85) | SLC6A5NOD1FOLH1ITGB3ITGA2B | |
| SCHEMBL15474 | 0.94 | SLC6A5 (0.85) | SLC6A5NOD1FOLH1ITGB3ITGA2B | |
| SCHEMBL1982744 | 0.94 | SLC6A5 (0.85) | SLC6A5NOD1FOLH1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121476611-A | Positive ion metabolism marker for thyroid-related eye diseases, product and application thereof | 华中科技大学同济医学院附属协和医院 | 2026-02-06 | — | — | CN | disclosed |
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AVANTOR PERFORMANCE MATERIALS, LLC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3980052-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-110420165-A | Quickly repair the MASQUE APAISANT HYDRATANT essence of postoperative skin | GUANGZHOU LENNON COSMETICS CO LTD | 2019-11-08 | — | — | CN | disclosed |
| CN-107405281-A | method for treating skin | 雅芳产品公司 | 2017-11-28 | — | — | CN | disclosed |
| EP-2744510-A1 | N-GLYCOSYLATED INSULIN ANALOGUES | Merck Sharp & Dohme Corp. (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2598170-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | Smartcells, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| EP-2598171-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | Smartcells, Inc. (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2013022721-A1 | N-GLYCOSYLATED INSULIN ANALOGUES | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | WO | disclosed |
| US-20120046223-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | SMARTCELLS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2012015687-A2 | DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO | SMARTCELLS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| EP-2408808-A1 | TERMINALLY-FUNCTIONALIZED CONJUGATES AND USES THEREOF | Smartcells, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| EP-2408470-A1 | Soluble non-depot insulin conjugates and uses thereof | Smartcells, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20120014908-A1 | TERMINALLY-FUNCTIONALIZED CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2012-01-19 | — | — | US | disclosed |
| US-20120010134-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20110281792-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SMARTCELLS, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110281939-A1 | POLYNUCLEOTIDE APTAMER-BASED CROSS-LINKED MATERIALS AND USES THEREOF | SMARTCELLS, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110281791-A1 | CRYSTALLINE INSULIN-CONJUGATES | SMARTCELLS, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110275560-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SMARTCELLS, INC. | 2011-11-10 | — | — | US | disclosed |
| WO-2010088276-A2 | POLYNUCLEOTIDE APTAMER-BASED CROSS -LINKED MATERIALS AND USES THEREOF | SMARTCELLS, INC. (US) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275560-A1 | SYNTHETIC CONJUGATES AND USES THEREOF | SLC2A4, SLC2A8, CD44 | SLC6A5 807/4885NOD1 2390/4885FOLH1 342/4885 |
| US-20120010134-A1 | SOLUBLE NON-DEPOT INSULIN CONJUGATES AND USES THEREOF | GPR119, IAPP, IRS1 | SLC6A5 1502/4885NOD1 1544/4885FOLH1 2010/4885 |
| US-20110281791-A1 | CRYSTALLINE INSULIN-CONJUGATES | IAPP, INSR, GPR119 | SLC6A5 1203/4885NOD1 2258/4885FOLH1 166/4885 |
| US-20110281792-A1 | BINDING-SITE MODIFIED LECTINS AND USES THEREOF | SIGLEC7, SIGLEC9, LGALS3BP | SLC6A5 1804/4885NOD1 870/4885FOLH1 354/4885 |
| US-20250339370-A1 | PERFORMANCE-ENHANCING EXCIPIENTS AND METHODS OF REDUCING VISCOSITY AND INCREASING STABILITY OF BIOLOGIC FORMULATIONS | AADAT, KYNU, PNISR | SLC6A5 3122/4885NOD1 3917/4885FOLH1 923/4885 |
| US-20110281939-A1 | POLYNUCLEOTIDE APTAMER-BASED CROSS-LINKED MATERIALS AND USES THEREOF | PNKP, ADAR, NCL | SLC6A5 2550/4885NOD1 1364/4885FOLH1 841/4885 |
| US-20120046223-A1 | EXOGENOUSLY TRIGGERED CONTROLLED RELEASE MATERIALS AND USES THEREOF | CD63, NSF, MSN | SLC6A5 981/4885NOD1 3491/4885FOLH1 286/4885 |
| US-20120014908-A1 | TERMINALLY-FUNCTIONALIZED CONJUGATES AND USES THEREOF | NPY1R, NTSR1, GRPR | SLC6A5 2018/4885NOD1 1433/4885FOLH1 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.